33069-62-4 (紫杉醇,Paclitaxel)

紫杉醇;TAXOL紫杉醇;合成紫杉醇;浆果赤霉素III;泰素;紫杉醇 GMP;Paclitaxel 紫杉醇;半合成紫杉醇;半合成紫杉醇峰鉴别 EP标准品;半合成紫杉醇系统适应性 EP标准品;醋氨己酸锌;天然紫杉醇;猪去氧胆酸;紫杉醇 EP标准品;紫杉醇 USP标准品;紫杉醇 标准品;紫杉醇（半合成）;紫杉醇（标准品）;紫杉醇 植物提取物,标准品,对照品;紫杉醇[半合成];紫杉醇峰鉴别 EP标准品;紫素;红豆杉提取物;特素;紫杉醇  天然紫杉醇提取物功效;泰素,紫素;紫杉醇，太素，特素，紫素;Paclitaxel 紫杉醇 试剂级，98%;紫杉醇(分析标准品);天然紫杉醇峰鉴别;

Paclitaxel;N-BENZYL-BETA-PHENYLISOSERINE ESTER;PACLITAXEL, TAXUS BREVIFOLIA;PACLITAXEL, TAXUS SPECIES;PACLITAXOL;TAXOL(TM);taxol a;TAXOL EQUIVALENT;PACLITAXEL(P);PACLITAXEL(P) PrintBack;PACLITAXEL(RG);Paclitaxel(Taxol);PACLITAXEL,Taxol;Taxol; (-)-Paclitaxel;ABI 007;Capxol;DHP 107;EMPAC;NK 105;Onxal;taxal;TAXUS;Desmocap11;7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete benzenepropanoic acid deriv.;BSPBio_002614;IDI1_000441;Spectrum5_001491;KBioGR_000492;KBio2_002016;Pharmakon1600-01503908;NCGC00024995-10;Spectrum4_001197;HMS3676G15;HMS1922K08;BRD-A28746609-001-05-7;KBio2_005628;AKOS015960460;UPCMLD-DP108:001;Bio1_000362;SDCCGMLS-0066823.P001;SR-01000597377-1;KBio3_000904;AB00172230_04;SR-01000597377;LMPR0104390001;KBio1_000441;NSC-758645;SDCCGSBI-0051168.P004;Bio2_000416;[2aR-[2a?,4?,4a?,6?,9?(?R*,?S*),11?,12?,12a?,12b?]]-?-(Benzoylamino)-?-hydroxy-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester benzenepropanoic acid;BP-23960;T 7402;HMS1792J13;SPECTRUM1503908;HMS1362J13;IDI1_002171;NCGC00024995-06;KBio3_000903;AB00172230-03;KBioSS_002016;LP01201;NCGC00024995-03;BRD-A28746609-001-04-0;SCHEMBL788187;NCGC00024995-43;NCGC00024995-05;AKOS015894977;HMS501G03;CCG-40266;KBioSS_000492;CHEMBL48;NS00003967;KBio2_003060;NCGC00024995-08;AC-675;Bio2_000896;NINDS_000441;KBioGR_001893;Paclitaxel (Taxol);NCGC00024995-13;NCGC00024995-02;KBio2_004584;HMS2093K15;HMS3412G15;AS-11004;Spectrum_001536;NSC758645;SMP1_000228;SBI-0051168.P003;BSPBio_001152;EU-0101201;s1150;NCGC00024995-07;P1632;KBio3_001834;UPCMLD-DP108:002;C07394;NCGC00024995-09;NCGC00024995-04;Lopac0_001201;SPBio_000943;BRD-A28746609-001-02-4;DivK1c_000441;KBio2_000492;Spectrum2_000872;KBio2_007152;Bio1_000851;Spectrum3_001057;Bio1_001340;AB00172230_05;Probes2_000350;HMS1990J13;Genexol-PM;PACLITAXEL [EP MONOGRAPH];ABI-007;(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-Tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (alphaR,betaS)-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate;5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXAHYDROXY-TAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYL-ISOSERINE;OncoGel;Anzatax;BRD-K62008436-001-03-1;HMS3712O12;3PPC5TL76P;Nanotaxel;KBioGR_002509;CAS-33069-62-4;L01CD01;(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,;CHEBI:45863;Cypher select;(NAB)-Paclitaxel;AB00513812-03;ABRAXANE COMPONENT PACLITAXEL;5beta,20-Epoxy-1,2 alpha, 4,7beta, 10beta, 13alpha-hexahydroxy tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine;Cynviloq;NCGC00164367-04;MBT 0206;CHEMBL428647;[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate;Paclitaxel-SSMM-VIP;Ebetaxel;NCGC00164367-01;(2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate;HMS2090D07;PACLITAXEL [JAN];BRD-K62008436-001-05-6;Paclitaxel,(S);SMR000857385;7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.;PACLITAXEL [USP MONOGRAPH];NSC-125973;DRG-0190;Paclitaxel [USAN:USP:INN:BAN];Bris Taxol;Paclical;P-SSMM-VIP;Taxus Express;PACLITAXEL [VANDF];SDP-013;BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-;GS-6554;KBio2_002509;D00491;Yewtaxan;nab-paclitaxel;(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester;SCHEMBL3976;Q-201533;Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder;Q423762;Genaxol;Pacligel;Paclitaxel, from Taxus yannanensis, powder;Infinnium;PACLITAXEL [GREEN BOOK];Taxol (Paclitaxel);CCRIS 8143;P88XT4IS4D;Taxol (TN) (Bristol Meyers);PACLITAXEL [WHO-DD];BIDD:PXR0046;HSDB 6839;PACLITAXELPACLITAXEL;MLS002695976;Genetaxyl;,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester;7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.;DTS-301;TAX-11-EN-9-ONE, 5BETA,20-EPOXY-1,2ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE;DTXCID603413;PACLITAXEL (EP MONOGRAPH);Tax-11-en-9-one,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine;Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine;EN300-117275;Nanoxel;PACLITAXEL [MART.];Paclitaxel, from semisynthetic (from Taxus sp.), >=97%;TaxAlbin;PACLITAXEL [HSDB];(2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12;DHP-208;KBio3_002987;Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard;Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2a-alpha,4-beta,4a-beta,6-beta,9-alpha(alpha-R*,beta-S*),11-alpha,12-alpha,12a-alpha, 12b-alpha))-;Coroflex Please;NCGC00164367-03;PACLITAXEL [MI];AKOS015969673;Tocosol Paclitaxel;Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha- hexahydroxy-, 4,10-diacetate 2-benzoate, 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine;(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate;Tox21_112107;Plaxicel;1203669-79-7;PACLITAXEL (MART.);IG 001;MFCD00869953;EndoTAG-1;Sindaxel;NCGC00164367-10;Paclitaxel, European Pharmacopoeia (EP) Reference Standard;BMS-181339-01;paclitaxelum;Pacliex;HY-B0015;M02242;(2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate;AB00513812-02;PACLITAXEL (USP-RS);NK-105;Cyclopax;PACLITAXEL (USP MONOGRAPH);Prestwick3_000155;Taxus Liberte;AKOS007930675;Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (alphaR,betaS)-;(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate;ORAXOL COMPONENT PACLITAXEL;NSC-745099;HMS2095O12;Liposome-entrapped paclitaxel easy-to-use;N88686;(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate;EndoTAG 1;SR-01000075350;ABI-007 COMPONENT PACLITAXEL;NSC 125973;PACLITAXEL (USP IMPURITY);BMS-181339;ANX-513;CS-1145;Taxol, Bris;PACLITAXEL IMPURITY L [EP IMPURITY];RCINICONZNJXQF-MZXODVADSA-N;Paclitaxel protein-bound particles for injectable suspension (albumin-bound);33069-62-4;Nova-12005;Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-;PACLITAXEL [INN];Paxene;4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate;PACLITAXEL [ORANGE BOOK];BDBM50001839;Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13;12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine;Xorane;(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine;KBio2_005077;Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-;NCGC00164367-05;-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(aR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-;MEGxp0_001940;Paxoral;(1S,2S,3R,4S,5R,7S,8S,10R,13S)-4,10-Diacetoxy-2-benzoyloxy-5,20-epoxy-1,7-dihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate;Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material;MLS002154218;SR-01000075350-3;LEP-ETU;PACLITAXEL [USAN];SR-01000075350-7;5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine;QW-8184;Paclitaxel, United States Pharmacopeia (USP) Reference Standard;DHP-107;BPBio1_000320;MPI-5018;BRD-K62008436-001-22-1;[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate;Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester, (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alphaR*,betaS*),11alpha,12alpha,12aalpha,12balpha))-;Zisu;MBT-0206;NCI60_000601;Paxceed;Taxus stent;CCG-220155;Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H;4alpha,10beta-bis(acetyloxy)-13alpha-((2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy)-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate;UNII-P88XT4IS4D;Paclitaxel, Antibiotic for Culture Media Use Only;[diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate;Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-;DTXSID9023413;Intaxel;AKOS025312303;NSC125973;ACon1_002231;Paclitaxel semi-synthetic for system suitability, European Pharmacopoeia (EP) Reference Standard;Padexol;PACLITAXEL [EMA EPAR];Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-;Paclitaxel semi-synthetic for peak identification, European Pharmacopoeia (EP) Reference Standard;Paclitaxel; 5beta,20-Epoxy-1,7beta-dihydroxy-9-oxotax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Taxol; Docetaxel Anhydrous Impurity F; Docetaxel Impurity F;Abraxane (albumin-bound suspension);DB01229;KBio2_007645;cMAP_000068;Paclitaxel (taxus canadensis);QW 8184;Abraxane;BMS 181339-01;PACLITAXEL [USP-RS];SR-01000075350-9;OAS-PAC-100;GTPL2770;ABI 007 COMPONENT PACLITAXEL;Genexol;Paclitaxel, From Taxus brevifolia, 95%;NCGC00164367-02;BSPBio_000290;SR-01000075350-6;Tax-11-en-9-one, 5beta,20-epoxy-1,2alpha,4,7beta,10beta,13alpha-hexahydroxy-, 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine (8CI);1ST000431;Paclitaxel (JAN/USP/INN);Abraxane (TN);SR-01000075350-1;HMS2231A16;4,7beta,10beta-tris(acetyloxy)-13alpha-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate;LipoPac;,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)- (9CI);NAB-PACLITAXEL COMPONENT PACLITAXEL;TAXOL (TN);(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate;Paclitaxel (USAN:USP:INN:BAN);Onxol;Mitotax;KBioSS_002517;AB00513812;NSC745099;Abraxane I.V. Suspension;TAX-11-EN-9-ONE, 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXA-HYDROXY-, 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE;PACLITAXEL [USP IMPURITY];Epitaxol;MLS001097642;SMR000578108;7-epi-Taxol;Taxol; Paclitaxel;MLSMR;Paclitaxel natural for peak identification;Paclitaxel?;

MFCD00869953

RCINICONZNJXQF-MZXODVADSA-N

InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1

O=C(C1=CC=CC=C1)N[C@@H](C2=CC=CC=C2)[C@H](C(O[C@@H]3C(C)=C([C@@H](OC(C)=O)C([C@@]4(C)[C@]([C@@](CO5)(OC(C)=O)[C@@]5([H])C[C@@H]4O)([H])[C@@H]6OC(C7=CC=CC=C7)=O)=O)C(C)(C)[C@@]6(O)C3)=O)O

1420457

205-285-7

2932999021

紫杉醇主要适用于卵巢癌和乳腺癌，对肺癌、大肠癌、黑色素瘤、头颈部癌、淋巴瘤、脑瘤也都有一定疗效。

用途

1420457

18(5)5,622